148 related articles for article (PubMed ID: 37039042)
1. Muramyl dipeptide CD10 monoclonal antibody immunoconjugates inhibited acute leukemia in nude mice.
Wang Y; Jin X; Sun Y; Zhao Y; Qu Z; Wang L; Sun L
Biosci Rep; 2023 Apr; 43(4):. PubMed ID: 37039042
[TBL] [Abstract][Full Text] [Related]
2. Muramyl dipeptide and anti-CD10 monoclonal antibody immunoconjugate enhances anti-leukemia immunity of T lymphocytes.
Wang LZ; Zhang L; Wang LL; Lu Y; Chen L; Sun Y; Zhao HG; Song L; Sun LR
APMIS; 2016 Sep; 124(9):800-4. PubMed ID: 27307219
[TBL] [Abstract][Full Text] [Related]
3. Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.
Wang LZ; Sun LR; Zhao YX; Wang LL
Int Immunopharmacol; 2011 Sep; 11(9):1211-9. PubMed ID: 21492747
[TBL] [Abstract][Full Text] [Related]
4. Marked enhancement of macrophage activation induced by synthetic muramyl dipeptide (MDP) conjugate using monoclonal anti-MDP antibodies.
Leclerc C; Bahr GM; Chedid L
Cell Immunol; 1984 Jul; 86(2):269-77. PubMed ID: 6733783
[TBL] [Abstract][Full Text] [Related]
5. Muramyl Dipeptide modulates differentiation, maturity of dendritic cells and anti-tumor effect of DC-mediated T cell in acute leukemia children.
Wang LZ; Li XL; Pang XY; Sun LR
Hum Vaccin; 2011 Jun; 7(6):618-24. PubMed ID: 21445005
[TBL] [Abstract][Full Text] [Related]
6. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by muramyl dipeptide of in vitro nude mice responses to a T-dependent antigen.
Leclerc C; Bourgeois E; Chedid L
Immunol Commun; 1979; 8(1):55-64. PubMed ID: 311334
[TBL] [Abstract][Full Text] [Related]
8. Activation of mouse macrophages by muramyl dipeptide coupled with an anti-macrophage monoclonal antibody.
Midoux P; Martin A; Collet B; Monsigny M; Roche AC; Toujas L
Bioconjug Chem; 1992; 3(2):194-9. PubMed ID: 1515473
[TBL] [Abstract][Full Text] [Related]
9. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
[TBL] [Abstract][Full Text] [Related]
10. Lipophilic derivative of muramyl dipeptide is more active than muramyl dipeptide in priming macrophages to release superoxide anion.
Pabst MJ; Cummings NP; Shiba T; Kusumoto S; Kotani S
Infect Immun; 1980 Aug; 29(2):617-22. PubMed ID: 6260655
[TBL] [Abstract][Full Text] [Related]
11. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
12. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
13. Differential role of interferon-gamma in the potentiating effect of muramyl peptides for enhanced responses to lipopolysaccharide in mice: effect of cyclosporin A.
Beigneux A; Huang J; Le Contel C; Heremans H; Parant MA
J Interferon Cytokine Res; 1995 Apr; 15(4):359-65. PubMed ID: 7627811
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of chemiluminescence by synthetic muramyl dipeptide and analogs.
Masihi KN; Azuma I; Brehmer W; Lange W
Infect Immun; 1983 Apr; 40(1):16-21. PubMed ID: 6832829
[TBL] [Abstract][Full Text] [Related]
16. Production of tumor necrosis factor in nude mice by muramyl peptides associated with bacterial vaccines.
Noso Y; Parant M; Parant F; Chedid L
Cancer Res; 1988 Oct; 48(20):5766-9. PubMed ID: 3167834
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Fc receptor expression in guinea pig peritoneal exudate macrophages by muramyl dipeptide or lipopolysaccharide.
Yagawa K; Kaku M; Ichinose Y; Nagao S; Tanaka A; Aida Y; Tomoda A
J Immunol; 1985 Jun; 134(6):3705-11. PubMed ID: 2985692
[TBL] [Abstract][Full Text] [Related]
18. NOD2 ligation subverts IFN-alpha production by liver plasmacytoid dendritic cells and inhibits their T cell allostimulatory activity via B7-H1 up-regulation.
Castellaneta A; Sumpter TL; Chen L; Tokita D; Thomson AW
J Immunol; 2009 Dec; 183(11):6922-32. PubMed ID: 19890047
[TBL] [Abstract][Full Text] [Related]
19. Some cellular and pathophysiological correlates of the inflammatory effects of a synthetic immunomodulatory agent, muramyl dipeptide (MDP).
Zídek Z; Franková D; Masek K
Agents Actions; 1993 Jan; 38(1-2):106-15. PubMed ID: 8386899
[TBL] [Abstract][Full Text] [Related]
20. Modulation of lipopolysaccharide-induced cytokine gene expression in mouse bone marrow-derived macrophages by muramyl dipeptide.
Le Contel C; Temime N; Charron DJ; Parant MA
J Immunol; 1993 May; 150(10):4541-9. PubMed ID: 8482846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
